Colin Quinn, MD
he/him/his
Neurology
Accepting new patients
Sees patients age 18 and up
Penn Neuroscience Center - Neurology
View 1 additional location
Penn Medicine Provider

About me

  • Director, CMJC VAMC ALS Clinic
  • Co-Director, Penn Neuromuscular Center for Advanced Therapeutics (PNCAT)
  • Associate Director, Muscular Dystrophy Association (MDA) Clinic
  • Associate Professor of Clinical Neurology

Education and training

  • Medical School: University of Virginia
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Massachusetts General Hospital/Brigham and Women’s Hospital

What my patients think about me

Average Rating

217 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

October 2025
dr. cared
September 2025
knowledgeable, pleasant, and addresses all concerns
September 2025
he's a very good dr
September 2025
dr. quinn is knowledgeable, current on research for als and involved inpatient care.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Quinn is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Schiava M, Parkhurst Y, Henderson M, Polvikoski T, Valtcheva MV, Nishino I, Inoue M, Nishimori Y, Saito Y, Stojkovic T, Villar-Quiles RN, Romero NB, Evangelista T, Malfatti E, Souvannanorath S, Pegoraro E, Riguzzi P, Monforte M, Bortolani S, Torchia E, Sabatelli M, Tasca G, Straub V, Marini-Bettolo C, Guglieri M, Cetin H, Gelpi E, Klotz S, De Bleecker JL, Alonso-Jimenez A, Baets J, De Ridder W, De Jonghe P, Claeys KG, Thal DR, Bevilacqua JA, Luo S, Zhu W, Lin J, Papadimas G, Papadopoulos C, Zamba-Papanicolaou E, Xirou S, Pal E, Rodolico C, Kostera-Pruszczyk A, Kierdaszuk B, Kaminska A, Muelas N, Vilchez JJ, Domínguez-González C, Hernandez-Lain A, Alonso-Perez J, Nedkova-Hristova V, Aledo C, Oldfors A, Badrising UA, Kushlaf H, Lloyd TE, Ikenaga C, Alfano LN, Quinn CC, Walk D, Vorgerd M, Weihl C, Olivé M, Diaz-Manera J; VCP International Study Group. Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy , Neurol Genet, 11: 2025,e200265


Fournier CN, Quinn CC. The Amyotrophic Lateral Sclerosis Multidisciplinary Clinic: Broke but Not Broken , Neurology, 104: 2025,e210189


Austin MA, Supple GE, Carrell S, Quinn C, Elman L, Nazarian S. Atrial Fibrillation and Flutter in a Contemporary Cohort of Patients With Myotonic Muscular Dystrophy , JACC Clin Electrophysiol: 2025


Fournier CN, Levine M, Simmons K, García-Santibáñez RC, Rowland A, Quinn CC, Ho DT, Bedlack RS, Glass JD. ALS Motor Observational Telemedicine Objective Rasch-Built Assessment: A Quantitative Scale for the Era of Teleneurology , Neurol Clin Pract: 2025


Kishnani PS, Byrne BJ, Claeys KG, Díaz-Manera J, Dimachkie MM, Kushlaf H, Mozaffar T, Roberts M, Schoser B, Hummel N, Kopiec A, Holdbrook F, Shohet S, Toscano A; PROPEL Study Group. Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease , J Patient Rep Outcomes, 8: 2024,132


Morganroth J, Bardakjian TM, Dratch L, Quinn CC, Elman LB. Enhancing Clinical Infrastructure for the Delivery of Intrathecal and Genetic Therapies: A Qalsody (Tofersen) Model for Patients With SOD1-ALS , Neurol Clin Pract: 2024


Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C; ORARIALS-01 trial team. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial , Lancet Neurol: 2024


Quinn C, Baer M, Amado DA, Kelley M, Elman L. A single ALS center experience with clinical use of sodium phenylbutyrate-taurursodiol , Muscle Nerve: 2024


Baldwin A, Copeland J, Azage M, Dratch L, Johnson K, Paul RA, Amado DA, Baer M, Deik A, Elman LB, Guo M, Hamedani AG, Irwin DJ, Lasker A, Orthmann-Murphy J, Quinn CC, Tropea TF, Scherer SS, Shinohara RT, Hamilton RH, Ellis CA. Disparities in Genetic Testing for Neurologic Disorders , Neurology, 102: 2024,e209161


Dratch L, Bardakjian TM, Johnson K, Babaian N, Gonzalez-Alegre P, Elman L, Quinn C, Guo MH, Scherer SS, Amado DA. The Importance of Offering Exome or Genome Sequencing in Adult Neuromuscular Clinics , Biology (Basel), 13: 2024,93